Since galactose residues can bind to the asialoglycoprotein receptor (ASGPR), an endocytotic cell surface receptor expressed by mammal hepatocytes, and trigger the import of molecules conjugated with galactose across the cellular plasma membrane [28], liposomes modified with galactosylate may target to hepatocytes via ASGPR-mediated way, thus provide significant therapeutic benefits to hepatic disease. This evidence concerns the gene CD177 and liver disorder.